Company intelligence / Profile preview

Biobot Surgical

Singapore, Central, Singaporebiobotsurgical.com ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Biobot Surgical has developed the iSR'obot Mona Lisa system for robotic-assisted transperineal prostate biopsy and ablation. The device has received multiple regulatory clearances (FDA, CE mark, TGA in Australia, HSA in Singapore) and has been used in over 25,000 procedures globally. Clinical results highlight improved accuracy (<1 mm), higher detection rates compared to transrectal biopsies due to MRI/ultrasound fusion imaging, minimal infection rates due to percutaneous approach.

Therapeutic areas: OncologyOther
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Collaborations with international urologists and centers of excellenceZIG Ventures as a strategic partner/investor

Beyond the preview

Go deeper on Biobot Surgical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biobot Surgical.

Explore the full profile